We found that NF-κB transcription activity was significantly inhibited in ABC-DLBCL cells based on the diminished expression of NF-κB target genes, including Bcl-xl protein expression (Figure 3A) and the mRNA levels of Bcl-xl, IL-6, and IL-10 (Figure 3B), in response to z-VRPR-fmk treatment. The gene discussed is BCL2L1; the disease is diffuse large B-cell lymphoma.